Home » Topics » Regulatory » EMA

EMA
RSS

AOP Orphan completes enrollment in phase III trial of ropeginterferon alfa 2b

March 9, 2015

CHMP recommends approval of Humira for severe chronic plaque psoriasis in children

March 3, 2015

EMA committee recommends approval of Avastin plus chemotherapy for advanced cervical cancer

March 3, 2015

EMA accepts MAA for Santen's intravitreal sirolimus for non-infectious uveitis

March 2, 2015

Takeda withdraws new European Rienso submission

March 2, 2015

EMA committee recommends new approval of Vectibix in metastatic colorectal cancer

March 2, 2015

EMA's CHMP backs approval of Jinarc for rare kidney disease

March 2, 2015

CHMP recommends conditional marketing approval of ceritinib

March 2, 2015

EMA awards orphan drug designation to alvocidib for AML

Feb. 26, 2015

EMA grants orphan drug status to Theravectys vaccine for ATL/L

Feb. 9, 2015

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...